Who
Robert J. Carpenter
Director
Company insider
Files Form 4 as: Director, Immuneering; Director, Genzyme.
In numbers
- Trades disclosed
- 76
- Buys
- 1
- Sells
- 10
- Bought
- $4.9M
- Sold
- $5.4M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 9 Oct 2002
- Last trade
- 11 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 11 Jun 2026 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,350 at $0.00 | filing |
| 11 Jun 2026filed 11 Jun 2026 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,350 at $0.00 | filing |
| 13 Jun 2025filed 16 Jun 2025 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,350 at $0.00 | filing |
| 12 Jun 2024filed 13 Jun 2024 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,350 at $0.00 | filing |
| 14 Jun 2023filed 15 Jun 2023 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 21 Jun 2022filed 23 Jun 2022 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,200 at $0.00 | filing |
| 3 Aug 2021filed 4 Aug 2021 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Code C | —217,173 | filing |
| 3 Aug 2021filed 4 Aug 2021 | IMRX ImmuneeringBiotechnology | SEC FORM 4 Bought | $4.9M325,000 at $15.00 | filing |
| 3 Aug 2021filed 4 Aug 2021 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code C | —94,585 | filing |
| 3 Aug 2021filed 4 Aug 2021 | IMRX Immuneeringoption or derivative · Biotechnology | SEC FORM 4 Code C | —122,588 | filing |
| 4 Apr 2011filed 6 Apr 2011 | Genzymeoption or derivative | SEC FORM 4 Code M | —2,375 at $0.00 | filing |
| 4 Apr 2011filed 6 Apr 2011 | Genzymeoption or derivative | SEC FORM 4 Code D | $585K18,000 at $32.52 | filing |
| 4 Apr 2011filed 6 Apr 2011 | Genzymeoption or derivative | SEC FORM 4 Code D | $367K7,125 at $51.52 | filing |
| 4 Apr 2011filed 6 Apr 2011 | Genzymeoption or derivative | SEC FORM 4 Code D | $440K7,500 at $58.66 | filing |
| 4 Apr 2011filed 6 Apr 2011 | Genzymeoption or derivative | SEC FORM 4 Code D | $514K7,500 at $68.48 | filing |
| 4 Apr 2011filed 6 Apr 2011 | Genzymeoption or derivative | SEC FORM 4 Code D | $932K15,000 at $62.16 | filing |
| 4 Apr 2011filed 6 Apr 2011 | Genzymeoption or derivative | SEC FORM 4 Code D | $878K15,000 at $58.50 | filing |
| 4 Apr 2011filed 6 Apr 2011 | Genzymeoption or derivative | SEC FORM 4 Code D | $945K15,000 at $62.98 | filing |
| 4 Apr 2011filed 6 Apr 2011 | Genzymeoption or derivative | SEC FORM 4 Code D | $395K9,000 at $43.90 | filing |
| 4 Apr 2011filed 6 Apr 2011 | Genzymeoption or derivative | SEC FORM 4 Code D | $42K1,010 at $41.51 | filing |
News
No headline names them, or the companies they trade most, lately.